Delafloxacin: First Global Approval

Delafloxacin (Baxdela™) is a fluoroquinolone antibacterial with activity against both gram-positive and gram-negative pathogens being developed by Melinta Therapeutics. The drug is being investigated or considered as a treatment for various bacterial infections and in June 2017 received approval in...

Descripción completa

Detalles Bibliográficos
Autor principal: Markham, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
AdisInsight Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208769/
https://www.ncbi.nlm.nih.gov/pubmed/28748399
http://dx.doi.org/10.1007/s40265-017-0790-5
_version_ 1783366772743733248
author Markham, Anthony
author_facet Markham, Anthony
author_sort Markham, Anthony
collection PubMed
description Delafloxacin (Baxdela™) is a fluoroquinolone antibacterial with activity against both gram-positive and gram-negative pathogens being developed by Melinta Therapeutics. The drug is being investigated or considered as a treatment for various bacterial infections and in June 2017 received approval in the USA for the treatment of acute bacterial skin and skin structure infections. This article summarizes the milestones in the development of delafloxacin leading to this first global approval for the treatment of acute bacterial skin and skin structure infections.
format Online
Article
Text
id pubmed-6208769
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-62087692018-11-09 Delafloxacin: First Global Approval Markham, Anthony Drugs AdisInsight Report Delafloxacin (Baxdela™) is a fluoroquinolone antibacterial with activity against both gram-positive and gram-negative pathogens being developed by Melinta Therapeutics. The drug is being investigated or considered as a treatment for various bacterial infections and in June 2017 received approval in the USA for the treatment of acute bacterial skin and skin structure infections. This article summarizes the milestones in the development of delafloxacin leading to this first global approval for the treatment of acute bacterial skin and skin structure infections. Springer International Publishing 2017-07-26 2017 /pmc/articles/PMC6208769/ /pubmed/28748399 http://dx.doi.org/10.1007/s40265-017-0790-5 Text en © Springer Nature 2018, corrected publication October/2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
spellingShingle AdisInsight Report
Markham, Anthony
Delafloxacin: First Global Approval
title Delafloxacin: First Global Approval
title_full Delafloxacin: First Global Approval
title_fullStr Delafloxacin: First Global Approval
title_full_unstemmed Delafloxacin: First Global Approval
title_short Delafloxacin: First Global Approval
title_sort delafloxacin: first global approval
topic AdisInsight Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208769/
https://www.ncbi.nlm.nih.gov/pubmed/28748399
http://dx.doi.org/10.1007/s40265-017-0790-5
work_keys_str_mv AT markhamanthony delafloxacinfirstglobalapproval

Ejemplares similares